peoplePerson
Dongsheng Tu
Dongsheng Tu is the statistician behind decades of CCTG trials, including the erlotinib and cetuximab studies that changed lung and colorectal cancer care.
Dongsheng Tu has been senior biostatistician for Canadian Cancer Trials Group studies including BR.21 (erlotinib in NSCLC) and CO.17 (cetuximab in colorectal cancer), and contributes to methodology for adaptive and biomarker-driven trials.
Role
Senior Biostatistician, Canadian Cancer Trials Group; Professor, Queen's University
Institution
Specialisms
BiostatisticsClinical trial designSurvival analysis
| Title | Journal | Year |
|---|---|---|
| Cetuximab for the treatment of colorectal cancer (CO.17) | NEJM | 2007 |